These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 3275471)

  • 21. [A new group of anxiolytic drugs with a mechanism of action different from that of benzodiazepine derivatives].
    Kostowski W; Płaźnik A
    Pol Tyg Lek; 1988 Dec 19-26; 43(51-52):1647-9, 1683. PubMed ID: 2908340
    [No Abstract]   [Full Text] [Related]  

  • 22. Treating the anxiety: therapeutic options in obsessive compulsive disorder.
    Greist JH
    J Clin Psychiatry; 1990 Nov; 51 Suppl():29-34. PubMed ID: 2146255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Behavioral, neuroendocrine, and biochemical effects of 5-hydroxytryptophan administration in panic disorder.
    den Boer JA; Westenberg HG
    Psychiatry Res; 1990 Mar; 31(3):267-78. PubMed ID: 2139731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The neurochemistry of anxiety: an update.
    Nutt DJ; Glue P; Lawson C
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(5):737-52. PubMed ID: 1963497
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antidepressant & anxiolytic activities of N-(pyridin-3-yl) quinoxalin-2-carboxamide: A novel serotonin type 3 receptor antagonist in behavioural animal models.
    Pandey DK; Devadoss T; Modak N; Mahesh R
    Indian J Med Res; 2016 Oct; 144(4):614-621. PubMed ID: 28256473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [New discoveries on antidepressive treatment: serotonin is the key].
    Evenden J
    Lakartidningen; 1997 Sep; 94(38):3262-6. PubMed ID: 9379793
    [No Abstract]   [Full Text] [Related]  

  • 27. Monoamine oxidase inhibitors in obsessive-compulsive disorder.
    Jenike MA; Surman OS; Cassem NH; Zusky P; Anderson WH
    J Clin Psychiatry; 1983 Apr; 44(4):131-2. PubMed ID: 6833198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The selective effects of serotonin reuptake inhibitors.
    Montgomery SA
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():353A-354A. PubMed ID: 1498869
    [No Abstract]   [Full Text] [Related]  

  • 29. [Antidepressive agents and anxiety].
    Lépine JP; Chignon JM
    Rev Prat; 1991 Mar; 41(9):814-20. PubMed ID: 2047718
    [No Abstract]   [Full Text] [Related]  

  • 30. Behavioral pharmacology: potential antidepressant and anxiolytic properties.
    Wesołowska A; Jastrzębska-Więsek M
    Int Rev Neurobiol; 2011; 96():49-71. PubMed ID: 21329784
    [No Abstract]   [Full Text] [Related]  

  • 31. Panic disorder: the potential role of serotonin reuptake inhibitors.
    Sheehan DV; Zak JP; Miller JA; Fanous BS
    J Clin Psychiatry; 1988 Aug; 49 Suppl():30-6. PubMed ID: 3045109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Creating more effective antidepressants: clues from the clinic.
    Rasmussen K
    Drug Discov Today; 2006 Jul; 11(13-14):623-31. PubMed ID: 16793531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of serotonergic agents in the clinical assessment of central serotonin function.
    Murphy DL; Mueller EA; Garrick NA; Aulakh CS
    J Clin Psychiatry; 1986 Apr; 47 Suppl():9-15. PubMed ID: 3514586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Platelet serotonin uptake in panic disorder: comparison with normal controls and the effect of treatment.
    Norman TR; Gregory MS; Judd FK; Burrows GD; McIntyre IM
    Aust N Z J Psychiatry; 1988 Dec; 22(4):390-5. PubMed ID: 2907288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is it possible to modify serotonin receptor sensitivity?
    Wirz-Justice A; Krauchi K; Lichtsteiner M; Feer H
    Life Sci; 1978 Sep; 23(12):1249-54. PubMed ID: 309538
    [No Abstract]   [Full Text] [Related]  

  • 36. Therapeutic applications and mechanisms of action of monoamine oxidase inhibitor and heterocyclic antidepressant drugs.
    Goodman WK; Charney DS
    J Clin Psychiatry; 1985 Oct; 46(10 Pt 2):6-24. PubMed ID: 3900056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serotonin and treatment in obsessive-compulsive disorder.
    March JS; Gutzman LD; Jefferson JW; Greist JH
    Psychiatr Dev; 1989; 7(1):1-18. PubMed ID: 2508084
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antidepressants in panic disorders.
    Liebowitz MR
    Br J Psychiatry Suppl; 1989 Oct; (6):46-52. PubMed ID: 2695127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluvoxamine in the treatment of panic disorder with obsessive-compulsive symptoms.
    Servant D; Bailly D; Parquet PJ
    Am J Psychiatry; 1988 Sep; 145(9):1174-5. PubMed ID: 3137830
    [No Abstract]   [Full Text] [Related]  

  • 40. The possible role of 5-HT(1B/D) receptors in psychiatric disorders and their potential as a target for therapy.
    Moret C; Briley M
    Eur J Pharmacol; 2000 Sep; 404(1-2):1-12. PubMed ID: 10980257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.